MedTrace Logo

Sitagliptin in Recurrent/Progressive Grade 4 Glioma

NCT07541781 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2026-04-21

No results posted yet for this study

Summary

Sitagliptin, when combined with standard-of-care drug bevacizumab, is being tested to 1) find out if it is effective at treating gliomas that have returned or progressed after treatment, and 2) find out what the highest dose of sitagliptin is appropriate to give when combined with bevacizumab.

Conditions

Interventions

DRUG

Sitagliptin

Sitagliptin, PO dose to be determined by Phase I dose de-escalation, cycle length 28 days. Treatment until progression.

BIOLOGICAL

Bevacizumab

Bevacizumab, IV, 10 mg/kg days 1 and 15 every 28 days, until progression.

Sponsors & Collaborators

  • Kailin Yang, MD, PhD

    lead OTHER

Principal Investigators

  • Kailin Yang, MD, PhD · University of Iowa

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-31
Primary Completion
2029-05-01
Completion
2030-05-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07541781 on ClinicalTrials.gov